All News

There can be a myriad of reasons for the patterns observed in our study on alteration of migraine frequency and triggers during the pandemic, said Faraidoon Haghdoost, MD, a general practitioner and PhD student at The George Institute for Global Health in Sydney, Australia.

Much of the population experiences disordered breathing at night, explained Krishna M. Sundar, MD, clinical professor, Pulmonary Division, Department of Medicine, and medical director, Sleep-Wake Center, University of Utah.

Patients with psoriatic arthritis with enthesitis are more likely to have severe disease than patients without enthesitis, and they and their physicians are less likely to be satisfied with their treatments.

A skin test to detect clumping of alpha-synuclein, an abnormal protein suggested to have a central role in the pathogenesis of Parkinson disease, may assist in improving earlier detection of the condition, according to study findings.

A poster presented at this year’s annual meeting of the American Neurological Association demonstrates a likely greater risk of early-onset Alzheimer disease among persons living with HIV.

Patricia Salber, MD, MBA, of The Doctor Weighs in, speaks with Aledade co-founder, Farzad Mostashari, MD, about how his company is keeping physicians independent through value-based care.

Although their underlying mechanisms differ, finerenone reduces albuminuria to the same extent as SGLT2 inhibitors, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine.

In severely obese patients with previous myocardial infarction, metabolic surgery was associated with a lower risk of heart attack and new onset heart failure, according to study results published in Circulation.

Eli Lilly will end its clinical trial of bamlanivimab in patients hospitalized with coronavirus disease 2019; pros and cons of telemedicine and in-person care; new guidance on opioid use in pregnancy.

In a study published in Scientific Reports, researchers highlighted structural and functional brain differences among those who suffer menstrual-related migraine (MRM) and pure menstrual migraine (PMM).

A 72-year-old patient with Burkitt lymphoma was successfully treated with nivolumab after standard-of-care chemotherapy failed.

In a longitudinal cohort study, researchers identified 17 seemingly novel variants of the PDE6A retinitis pigmentosa gene, suggesting it may be amenable to gene therapy.

Can a population health framework focused on a certain set of patients with chronic disease (ie, chronic kidney disease [CKD]) improve care in the primary care setting?

With the impact of coronavirus disease 2019 (COVID-19) evident in patients with renal disease, a discussion at Kidney Week focused on ways to engage them in clinical trials.

Recognizing chronic kidney disease (CKD) can lead to earlier implementation of interventions among patients, ultimately reducing the risk of end stage renal disease, said Shweta Bansal, MD, FASN, associate professor of medicine in the nephrology division at the University of Texas Health Center at San Antonio.

Adults with obstructive sleep apnea who are not adherent to continuous positive airway pressure (CPAP) therapy were found to be more likely to be hospitalized with influenza than those who used CPAP.

AstraZeneca and Johnson & Johnson will restart trials of their vaccine candidates against coronavirus disease 2019 (COVID-19); the United States hits a record high 2-day total of COVID-19 infections; strategies can help ease stress amid the coming election.

Although renal replacement therapy is a clinically meaningful end point, trials must include numerous patients and follow them for long periods of time, said Kunihiro Matsushita, MD, an associate professor in the Department of Epidemiology and Division of Cardiology at Johns Hopkins University.

Understanding patients’ social determinants of health (SDOH), including their past experiences with discrimination and medical mistrust, can help improve patient-reported outcomes (PROs), according to new research.

During Kidney Week, various studies discussed not only the effect coronavirus disease 2019 (COVID-19) has on patients with end-stage renal disease (ESRD) but also new attacks of acute kidney injury (AKI) that can cause severe illness or even death.

This story was updated in February 2022 to show that this original story, published in October 2020, is out of date, and adds new information.

The use of estimated glomerular filtration rate (eGFR) equations in assessing chronic kidney disease (CKD) for Black patients may lead to underdiagnosis and undertreatment, according to a nephrologist speaking at Kidney Week.

Several symptoms patients with chronic kidney disease (CKD) experience are approved indications for medical cannabis, said Joshua L Rein, DO, FASN, a nephrologist at Mt. Sinai Hospital in New York City.

Initial preliminary efficacy and safety data are expected sometime next year, stated Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Andre Goy, MD, chairman, director, and chief of the Division of Lymphoma at John Theurer Cancer Center in Hackensack, NJ, discussed the potential benefits of using CAR T-cell therapies as a second-line treatment.

In reviewing the previous literature on health disparities in kidney disease, there is not a lot described in patients with kidney pathologies outside of ESKD and dialysis, said Jill Krissberg, MD, a pediatric nephrology fellow at Stanford University School of Medicine.

After conducting further genome-wide association studies (GWAS), we will be able to inform communities about the potential implications of gene expression in their kidneys, said Adriana Hung, MD, MPH, associate professor of medicine at Vanderbilt University in an interview with Bryce Rowan, a statistical genetic analyst.

Additional studies about roxadustat, a drug in the new class of hypoxia-inducible factor stabilizers, were released during Kidney Week; one of them explored its role in lowering cholesterol in patients with chronic kidney disease (CKD) and anemia.

New results from EMPEROR-Reduced presented at Kidney Week 2020.